Research Papers:

Serum microRNA profiles as prognostic biomarkers for HBV-positive hepatocellular carcinoma

Hao-Tu Zhu, Abdulbaqi M. E. Hasan, Rong-Bin Liu, Zi-Chen Zhang, Xiao Zhang, Jing Wang, Hai-Yun Wang, Fang Wang and Jian-Yong Shao _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:45637-45648. https://doi.org/10.18632/oncotarget.10082

Metrics: PDF 2316 views  |   HTML 2316 views  |   ?  


Hao-Tu Zhu1,*, Abdulbaqi M. E. Hasan1,*, Rong-Bin Liu1, Zi-Chen Zhang1, Xiao Zhang1, Jing Wang1, Hai-Yun Wang1, Fang Wang1, Jian-Yong Shao1

1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, and Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China

*These authors contributed equally to this work

Correspondence to:

Jian-Yong Shao, email: [email protected]

Keywords: serum microRNA, biomarkers, hepatocellular carcinoma, prognosis, deep sequencing

Received: January 28, 2016     Accepted: May 28, 2016     Published: June 15, 2016


To establish serum microRNA profiles as prognostic biomarkers in hepatocellular carcinoma patients (HCCs), we used deep sequencing to screen serum microRNAs in a discovery set .Twelve up-regulated serum miRNAs were selected for qPCR analysis in a training set. MiR-192-5p and miR-29a-3p were identified and associated with HCC prognosis. HCCs with high concentrations of miR-192-5p and miR-29a-3p had poorer overall survival (OS) and progression-free survival (PFS) than those with low concentrations. We calculated a prognostic index (PI) score and classified patients into low-, medium- and high-risk groups. OS and PFS among the 3 groups from the training set were significantly different (all P < 0.05). PI (PIOS, PIPFS) score was the only independent prognostic predictor for OS and PFS of HCCs in the training set. These results were further confirmed in a validation set. In conclusion, differentially expressed serum miRNAs can be helpful for predicting survival in HCCs.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10082